U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17ClN2OS
Molecular Weight 320.837
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ENCENICLINE

SMILES

ClC1=CC=CC2=C1SC(=C2)C(=O)N[C@H]3CN4CCC3CC4

InChI

InChIKey=SSRDSYXGYPJKRR-ZDUSSCGKSA-N
InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula C16H17ClN2OS
Molecular Weight 320.837
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22085888 | https://www.ecnp.eu/~/media/Files/ecnp/Projects%20and%20initiatives/Medicines%20Chest/EVP%206124.pdf

Encenicline (EVP-6124; MT-4666) acts as a potent partial and selective agonist at alpha-7 nicotinic acetylcholine receptor. Encenicline significantly improved memory function in animal models. FORUM Pharmaceuticals (formerly EnVivo Pharmaceuticals) is developing encenicline for the treatment of cognition disorders such as schizophrenia and for Alzheimer's disease.

Originator

Curator's Comment: # Bayer HealthCare

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.33 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
35.6 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.66 ng/mL
7 mg single, oral
dose: 7 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.588 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
100 ng/mL
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2800 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
358 ng × h/mL
7 mg single, oral
dose: 7 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
45.6 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8890 ng × h/mL
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
63 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
60.3 h
7 mg single, oral
dose: 7 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
52.6 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
60.6 h
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENCENICLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Encenicline was well tolerated at single doses up to 180 mg, and doses as low as 1 mg had dose- and time-dependent pharmacodynamic effects on the central nervous system. Results from a phase IIb trial showed that encenicline (2.0mg once daily) significantly improved cognition and clinical function in patients with mild-to-moderate Alzheimer's disease.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:30:13 GMT 2023
Edited
by admin
on Sat Dec 16 01:30:13 GMT 2023
Record UNII
5FI5376A0X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENCENICLINE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ENCENICLINE [USAN]
Common Name English
N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
Systematic Name English
BENZO(B)THIOPHENE-2-CARBOXAMIDE, N-(3R)-1-AZABICYCLO(2.2.2)OCT-3-YL-7-CHLORO-
Systematic Name English
MT-4666
Code English
Encenicline [WHO-DD]
Common Name English
(R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO(B)THIOPHENE-2-CARBOXAMIDE
Systematic Name English
EVP-6124
Code English
encenicline [INN]
Common Name English
MT4666
Code English
Code System Code Type Description
NCI_THESAURUS
C166844
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
CAS
550999-75-2
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
USAN
ZZ-156
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
PUBCHEM
46196517
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID701025836
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
SMS_ID
100000166184
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
INN
9775
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
CAS
1275596-71-8
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
SUPERSEDED
EVMPD
SUB180245
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
ChEMBL
CHEMBL2151572
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
WIKIPEDIA
Encenicline
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
FDA UNII
5FI5376A0X
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
DRUG BANK
DB11726
Created by admin on Sat Dec 16 01:30:13 GMT 2023 , Edited by admin on Sat Dec 16 01:30:13 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY